Currently Viewing:
Newsroom
Currently Reading
Positive Results From Phase 3 Study of Intuniv in Adults With ADHD
October 02, 2017 – AJMC Staff
New Paper Discusses Overcoming Barriers in Dermatology Treatment
October 01, 2017 – Alison Rodriguez
5 Takeaways for Payers and Providers From the NCCN Meeting on Quality Metrics
September 29, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: September 29, 2017
September 29, 2017
Early Imaging Can Identify Positive Immunotherapy Responders in Advanced Melanoma
September 28, 2017 – Surabhi Dangi-Garimella, PhD
Dr Michael Feld: New Liquid ADHD Treatment Has Benefits for Both Patients and Physicians
September 27, 2017
Report: Immune Checkpoint Proteins Are the Focus of Cancer Immunotherapy Development
September 27, 2017 – Alison Rodriguez
Patients With Moderate-to-Severe Atopic Dermatitis Significantly Improve With Dupixent
September 27, 2017 – Laura Joszt
What We're Reading: Policy on MRI Scans; Websites Illegally Selling Drugs; Alzheimer's Drug Failure
September 26, 2017 – AJMC Staff

Positive Results From Phase 3 Study of Intuniv in Adults With ADHD

AJMC Staff
Intuniv, a once-daily non-stimulant from Shire and Shionogi for adults with attention-deficit/hyperactivity disorder, met its primary endpoint and showed a superior change from baseline compared with placebo in a phase 3 study.
Shire and Shionogi’s Intuniv, a once-daily non-stimulant for adults with attention-deficit/hyperactivity disorder (ADHD), met its primary endpoint and showed a superior change from baseline compared with placebo in a phase 3 study.

The study included adults in Japan age 18 years and older who had ADHD. The drug is already approved as a treatment for patients between the ages of 6 and 17 years in Japan, the United States, and other countries, and is now being evaluated in Japan to treat ADHD in adults. Japan is the third-largest market for ADHD.

This 12-week, randomized, double-blind, multi-center, placebo-controlled study was the first clinical trial evaluating Intuniv in adults. A total of 201 adult patients with ADHD participated in the study. The study showed that Intuniv was superior to placebo based on a clinically administered ADHD rating scale total score. The treatment was also superior to placebo in improving patients’ global functioning.

“The positive topline results of this phase 3 study provide us with important data and insights regarding the clinical profile of Intuniv in adult patients with ADHD,” Brigitte Robertson, MD, vice president and head of Global Clinical Development, Neuropsychiatry, Shire, said in a statement. “We are evaluating the full data set, and excited to advance the development of INTUNIV as a non-stimulant treatment option for adults with ADHD in Japan, building on the established efficacy and safety data for ADHD in child and adolescent patients.”

Adverse events in the study were mild to moderate, and the researchers reported no new or unexpected safety findings compared with previous Intuniv studies. The most common adverse events were somnolence, dry mouth, blood pressure decrease, nospharyngitis, dizziness postural, and constipation.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up